Evidence map›Paper›PMID 24216246›Full record

Trial reportInternational journal of pharmaceutics2013

Prevention of vitamin D insufficiency in Switzerland: a never-ending story.

Sebastiano A G Lava, Giacomo D Simonetti, Alessandra A Bianchetti, Alessandra Ferrarini, Mario G Bianchetti

2 registry-linked trialsAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International journal of pharmaceutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06012266 phase2unknown statusstarted 2024, after this paper: background citation

Dose Rationale for Dapagliflozin and Empagliflozin in Paediatric Heart Failure: a Phase II.a Pharmacokinetics, Ease-of-swallow, Safety and Proof-of-concept Study Among Children 6-18 Years of Age

Ran2024Enrolled12Registered outcomes19Posted comparisons0ConditionsHeart FailureArmsDapagliflozin Tablet, Empagliflozin Tablets
Open the trial in the graph
NCT06643442 phase2not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Repurposing Empagliflozin for Duchenne Muscular Dystrophy - Associated Cardiomyopathy: a Pharmacokinetics, Safety and Proof-of-concept Study Among Children 6-18 Years of Age

TypeinterventionalSponsorSebastiano LavaRan2025 to 2027Enrolled12ConditionsDMD-associated Dilated CardiomyopathyArmsEmpagliflozin Tablets
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Prescription of vitamin D among Swiss pediatricians.European journal of pediatrics · 2019
    Article
  7. Observational
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sebastiano A G LavaDepartment of Pediatrics, Bellinzona and Mendrisio, and University of Bern, Bern, Switzerland; Division of Pediatric Nephrology, University Children's Hospital Bern and University of Bern, Bern, Switzerland. Electronic address: sebastiano.lava@bluewin.ch.
Giacomo D Simonetti
Alessandra A Bianchetti
Alessandra Ferrarini
Mario G Bianchetti

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ChildChild, PreschoolFemaleHumansInfant, NewbornMaleSwitzerlandTasteVitamin DVitamin D DeficiencyVitamin D

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.